Clinical Trials Arena May 24, 2024
MSD licenced the antibody-drug conjugate (ADC) therapy, sacituzumab tirumotecan, from China-based Sichuan Kelun-Biotech in 2022.
Merck & Co (MSD) has announced positive data for its antibody-drug conjugate (ADC) therapy, sacituzumab tirumotecan, from Phase II and III trials in lung and breast cancer indications, respectively.
The company released first-time data from the open-label Phase II trial (NCT05351788) in patients with advanced non-small cell lung cancer (NSCLC) along with additional data from the Phase III study (NCT05347134) with the ADC therapy in patients with advanced or metastatic triple-negative breast cancer.
The results will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from 31 May to 4 June.
Sacituzumab tirumotecan is a trophoblast cell-surface...
Today's Sponsors
Today's Sponsor